COMPANY PROFILE

Amoy Diagnostic

Explore full profile

Amoy Diagnostic focuses on molecular diagnostics for oncology precision medicine

Dongcheng District, ChinaFounded 2008Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2026

Revenue $100–500M Latest reported FY

Headcount 100–500 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Amoy Diagnostic

Amoy Diagnostics is a pioneering company in the field of cancer diagnostics, dedicated to revolutionizing cancer care through precision oncology. The company focuses on providing innovative and accurate diagnostic solutions that enable personalized treatment plans for cancer patients. Operating in the global healthcare market, Amoy Diagnostics serves a diverse range of clients including hospitals, research institutions, and healthcare providers. The business model revolves around the development and commercialization of advanced diagnostic tests, particularly those that utilize genomic information to tailor cancer treatments. Revenue is generated through the sale of diagnostic kits, partnerships with healthcare institutions, and collaborations with pharmaceutical companies. Amoy Diagnostics is committed to making precision medicine accessible to all, ensuring equitable access to cutting-edge cancer diagnostics and treatments.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2008
Headquarters: Dongcheng District, China
Employees: 112
Open positions: 1
Dealroom signal: 37.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Intellectual Property, Testing, Biotechnology, Oncology, Precision Medicine, Health Diagnostics, Spinout, Biotech and Pharma, medical testing, DT and LS, science-based
Client focus: b2b
Investment activity: 1 company, latest Oct 2025
Capital deployed: $6.9M
Preferred round: SERIES B
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
IPOExit	Aug 2017	$0	—	Undisclosed	—
SERIES B✓Equity / VC	Jan 2015	$6M	$24M	Undisclosed	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Amoy Diagnostic website traffic

Latest recorded traffic for Amoy Diagnostic is 2.2K monthly website visits, up 100% over the last three months. Amoy Diagnostic's team grew 2.8% over the past year.

Latest monthly visits2.2K 3-month web change+100% 1-year team growth+2.8%

Monthly website visitsDec 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Laboratory AssistantBuffalo, NY · Other · Aug 31, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PIPierianDxEnables clinical labs to deliver patient-specific diagnosis and treatments	St. Louis, United States	Acquired	32	$62M	$135M
VIVitroScanDedicated to delivering predictive diagnostic testing to support better informed treatment decisions for cancer patients	Leiden, Netherlands	Operational
MTMetabolomic TechnologiesCommitted to developing non-invasive in-vitro diagnostics to meet patients' greatest unmet needs	Edmonton, Canada	Operational
CTCARsgen TherapeuticsA leading immunotherapy company focused on the development of new chimeric antigen receptor	Xuhui District, China	Operational
ANAnchorDxAnchorDx is a precision medicine firm	Guangzhou, China	Operational
INInflammatixDeveloping novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system	Sunnyvale, United States	Operational
LLLeuko LabsDeveloping the first device for non-invasive white cell monitoring	Boston, United States	Operational
GEGeneticurePharmacogenomic tests to control large, chronic diseases faster than trial/error	Minneapolis, United States	Operational